AVIR insider trading

NasdaqGS Healthcare

Atea Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
116
Last 90 days
2
Buys / sells
8% / 12%
Market cap
$368.37M

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Company website: ateapharma.com

AVIR insider activity at a glance

FilingIQ has scored 116 insider transactions for AVIR since Jul 27, 2016. The most recent filing in our index is dated Mar 11, 2026.

Across the full history, 9 open-market purchases and 14 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AVIR insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Latest AVIR Form 4 filings

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

Frequently asked

How many insider trades does FilingIQ track for AVIR?
FilingIQ tracks 116 Form 4 insider transactions for AVIR (Atea Pharmaceuticals, Inc.), covering filings from Jul 27, 2016 onwards. 2 of those were filed in the last 90 days.
Are AVIR insiders net buyers or net sellers?
Across the full Form 4 history for AVIR, 9 transactions (8%) were open-market purchases and 14 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AVIR insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AVIR in?
Atea Pharmaceuticals, Inc. (AVIR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $368.37M.

Methodology & sources

Every AVIR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.